Roche Holding Company for Pharmaceutical Industries announced that it had obtained exceptional approval from the US government to launch a new examination to detect infection with the emerging corona virus (Covid-19) and described it will be ten times faster than the diagnostic methods currently used.
According to Bloomberg News, the US Food and Drug Administration has granted "exceptional approval to use" the new test, which is also available in Europe and other countries.
Roche, based in the Swiss city of Basel, said that the new test is available in two versions, the first of which has the number 8800 and can be used to diagnose the injury of 4128 patients per day, and the second bearing the number 6800 and can be used to diagnose the injury of 1440 patients per day.
"We have increased the diagnostic cutting rate by ten times," Bloomberg quoted Tomash Schenker, head of the Roche Diagnostic Unit, as saying in an interview.
Diagnosis is a key component in tackling the emerging coronavirus, as it allows health care officials to identify and isolate patients, even before symptoms appear, thereby reducing the scope of infection.